Tourettes syndrome
Drug research and approvals for tourettes syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 3 studies of tourettes syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 3
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 3 recruiting on ClinicalTrials.gov ↗- Investigating Changes in Premonitory Urges During Habit Reversal Training for TicsNCT06825520 · Not applicable · University of Utah · starts Feb 11, 2025
- Development and Application of a Diagnosis and Treatment System for Children's Brain Diseases Based on Knowledge Graphs…NCT06848959 · Not reported · Yun Liu,PhD · starts Jan 1, 2024
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchNCT04806620 · Not reported · Brain Inflammation Collaborative · starts Jul 5, 2023
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 31, 2019 | A multicenter, open-label, extension study intended to evaluate the long-term safety of ecopipam tablets in children and adolescent subjects with tourette¿s…ECOPIPAM (EBS-101) | EMALEX BIOSCIENCES, INC | Closed |
| May 31, 2019 | A multicenter, placebo-controlled, double-blind, randomized, parallel-group, phase 2b study to evaluate the efficacy and safety of ecopipam tablets in children…ECOPIPAM | EMALEX BIOSCIENCES, INC | Closed |
| Jan 17, 2019 | A well-controlled, fixed-dose study of tev-50717 (deutetrabenazine) for the treatment of tics associated with tourette syndromeDEUTETRABENAZINE (TEV-50717) | Teva Pharmaceutical Industries | Pending |
| Apr 10, 2018 | An open-label, long-term safety study including a double-blind, placebo-controlled, randomized withdrawal period of tev-50717 (deutetrabenazine) for the…DEUTETRABENAZINE (TEV-50717) | Teva Pharmaceutical Industries | Ongoing |
| Dec 21, 2017 | A randomized, double-blind, placebo-controlled study of tev-50717 (deutetrabenazine) for the treatment of tourette syndrome in children and adolescentsDEUTETRABENAZINE (TEV-50717) | Teva Pharmaceutical Industries | Closed |
| Dec 10, 2014 | A double-blind, randomized, placebo-controlled crossover pilot trial of medical cannabis in adults with tourette syndrome.DELTA-9-TETRAHYDROCANNABINOL-CANNABIDIOL | DR PAUL SANDOR | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA